| Subscribe To Our Free Newsletter |
Marketing firm Klaviyo lifts IPO price range, targets $9 bln valuation
A strong debut from SoftBank's Arm Holdings last week raised hopes of a rebound in the IPO market, but the lukewarm reception to Neumora Therapeutics has tempered some optimism.
